{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Verrica Pharmaceuticals Inc."},"Symbol":{"label":"Symbol","value":"VRCA"},"Address":{"label":"Address","value":"44 WEST GAY STREET,SUITE 400, WEST CHESTER, Pennsylvania, 19380, United States"},"Phone":{"label":"Phone","value":"+1 484 453-3300"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its lead product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a highly contagious and primarily pediatric viral skin disease, and common warts."},"CompanyUrl":{"label":"Company Url","value":"https://www.verrica.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"David Zawitz","title":"Chief Operating Officer"},{"name":"Gary Goldenberg","title":"Chief Medical Officer"},{"name":"Jayson M. Rieger","title":"President, Chief Executive Officer & Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}